The National Agency for Food and Drug Administration and Control (NAFDAC) has refuted claims that the antibiotic amoxicillin has been banned in Nigeria.
In a statement on Monday signed by its Director-General, Mojisola Adeyeye, the agency addressed a video circulating on social media suggesting that NAFDAC had secretly prohibited the sale and use of Amoxicillin in the country.
“NAFDAC has not banned Amoxicillin in Nigeria, either secretly or openly. As a responsible regulatory authority, the Agency publicly notifies Nigerians of any regulatory actions through official channels,” the statement read.
The agency explained that it communicates regulatory measures to the public via Recalls, Safety Alerts, Blacklists, and other safety notices whenever substandard, falsified, or affected products require intervention.
While some products may occasionally be withdrawn from the market, NAFDAC emphasized that these actions target specific brands or batches found to be substandard or non-compliant, and do not constitute a blanket ban on the medicine itself.
“In recent months, NAFDAC issued targeted safety alerts on certain brands and batches of Amoxicillin. In August 2025, Public Alert No. 24/2025 announced the recall of Amoxivue (Amoxicillin) 500mg capsules due to low Active Pharmaceutical Ingredient (API) content,” the statement said.
READ ALSO:
- Tinubu Swears In Tunji Disu As 23rd Inspector-General Of Police
- Euracare Defends Suspended Doctors Amid Investigation into Chimamanda Adichie’s Son’s Death
- US Embassy Suspends Visa Appointments In Abuja Amid Protest Concerns
- Sanwo-Olu Felicitates Adeboye At 84
- Apc Holds State Congress, Returns Ojelabi As Party Chairman
The agency added, “In October 2025, Public Alert No. 34/2025 addressed substandard batches of Astamocil and Astamentin suspensions, while Public Alert No. 35/2025 notified the public of substandard batches of Annmox and Jawamox suspensions. These actions were specific to identified products and do not constitute a ban on Amoxicillin.”
NAFDAC urged Nigerians to disregard misleading social media content and rely on official regulatory updates published through verified platforms. It also advised healthcare providers and patients to consult official recall and safety alerts before making treatment decisions.